The saliva collection & diagnostics market size is estimated to be USD 835.8 million in 2022 and is expected to witness a CAGR of 8.74% during the forecast period 2023-2033. The need for quick detection of chronic diseases, technical developments in the collection of newborn saliva, and expanding public awareness of the quick and secure diagnosis of various diseases are factors contributing to the market growth. However, high cost of blood sampling is expected to hinder the growth.

Expanding public awareness of the quick and secure diagnosis of various diseases is expected to propel the market growth during the projected period. For instance, Thermo Fisher Scientific, Inc. introduced the SpeciMAX Stabilized Saliva Collection Kit in September 2021 with the goal of collecting samples for study in a secure manner. For optimal sample collection, the kit includes a crew cap, a standard-size tube, and a spill-resistant funnel.

Increasing number of assays is projected to spur the market growth during the forecast period. Additionally, with the increase in assays, saliva collection may prove to be a best alternative method for the detection and diagnosis of a range of diseases, including cancers, and for identifying recurrences of disease, evaluating the effectiveness of treatments, and identifying patient risk. For instance, Salignostics introduced the SaliStick pregnancy test in November 2021, which provides findings based on saliva samples.

Segmentation

By Site of Collection

The market is categorized into submandibular/sublingual gland collection, parotid gland collection, and others. In 2022, the submandibular/sublingual gland collection segment accounted for the highest revenue share due to the rising number of sialolithiasis cases. The submandibular gland is where about 70.0% of unstimulated saliva is produced. Sialoliths, also referred to as salivary stones, are the most common disorder affecting the salivary glands in middle-aged adults. The submandibular gland accounts for around 80% of salivary sialolith development, followed by the parotid gland (6–15%) and the minor or sublingual salivary glands (2%). The parotid gland collection segment would experience significant expansion during the projection period. A rare kind of cancer, salivary gland cancer, appears in the tissue of the salivary gland. A lump or difficulty swallowing are indicators of this cancer. The parotid glands are the site of the most of benign cancers of the salivary glands. Imaging tests or biopsies, such as positron emission tomography scans, MRIs, and CT scans, are used to evaluate this problem. The market for saliva collection and diagnostics has grown as a result of the rising prevalence of parotid carcinoma.

By Application

The market is categorized into research, disease diagnostics, and forensic applications. In the global market, the disease diagnostics segment accounted for the largest revenue share in 2022 owing to rising incidence of diseases around the world and the corresponding rise in the demand for the appropriate diagnostic strategy. In 2019, there were 8,916 new instances of tuberculosis, 58,371 new cases of salmonella, 34,945 new cases of Lyme disease, and 371 new cases of meningococcal disease, according to CDC data. It is projected that the research segment would experience considerable expansion in the upcoming years due to higher investment from public and private market actors, and government in the R&D sector. For instance, in September 2022, Australian researchers from Yale School of Public Health claimed that saliva-based testing is effective for detecting SARS-CoV-2. Similar to this, miRNA was found in a sample of human saliva by Ahmedabad University researchers in October 2022. This discovery has shown promising results in the prediction of the prognosis of oral cancer.

By End User

The market is segmented into research institutes, diagnostic laboratories, pharmaceutical & biotechnology companies, and dentistry. In 2022, the diagnostic laboratories segment accounted for the largest revenue share owing to presence of a larger number of diagnostics labs and chains globally to fulfil the expanding requirements of clients. For instance, Eurofins Scientific introduced an ultra-rapid extraction-free RT-PCR technology in February 2021 that may be used with pharyngeal gargle matrices and a saliva sample. Similar to this, Synlab International GmbH reported in October 2020 that saliva sampling, a non-invasive sampling technique for RT-PCR testing for SARS-CoV-2 detection, had been successfully validated. The pharmaceutical and biotechnology companies are anticipated to have profitable expansion due to numerous product launches and strategic partnerships by the major market players.

Regional Markets

In 2022, North America region accounted for the highest revenue in the saliva collection & diagnostics market and is expected to maintain its dominance during the forecast period. This is attributed to the rising demand for saliva tests, increase in infectious disease incidences, and the introduction of novel products by market players operating in the region. The American Cancer Society estimates that 54,000 new cases of oral cancer or oropharyngeal cancer will be diagnosed in the United States in 2022, resulting in 11, 230 fatalities. Additionally, according to CDC estimates, there will be about 20,000 flu-related deaths in 2022, accounting for almost 9 million new cases that will be reported. Significant opportunities are being created in the region as a result of the rising prevalence of infectious diseases, which is driving up the demand for diagnostics and saliva collection. Asia Pacific region is predicted to experience the fastest growth rate due to substantial developments in the field of diagnostic testing. Home diagnostic tests have been widely adopted in India, and the trend is anticipated to continue in the years to come, according to a recent report published in April 2022.

Competitor Insights

Some of the key players operating in the saliva collection & diagnostics market are Abbott, Porex, Takara Bio Inc., Sarstedt AG & Co.KG, Neogen Corporation, Salimetrics, LLC, Thermo Fisher Scientific Inc., Oasis Diagnostics, Autogen, Inc., Arcis Bio, and Orasure Technologies.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, F. Hoffmann-La Roche Ltd. stated in December 2021 that it had received the CE certification for the use of samples with the Cobas SARS-CoV-2 qualitative test on the Cobas 6800/8800 systems.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including site of collection, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Saliva Collection & Diagnostics Market Report 2022 – 2033

Site of Collection (Revenue, USD Million), 2022 – 2033

• Submandibular/Sublingual Gland Collection
• Parotid Gland Collection
• Others

Application (Revenue, USD Million), 2022 – 2033

• Research
• Disease Diagnostics
• Forensic Applications

End user (Revenue, USD Million), 2022 – 2033

• Research Institutes
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Dentistry

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA